Duke ALS Clinic multi-disciplinary team identifies specific ALS symptoms and problems and provides a wide range of options for dealing with them.
From left: Amylyx Co-founders and Co-CEOs Justin Klee and Josh Cohen/Courtesy Amylyx . The FDA’s Peripheral and Central Nervous System Drugs Advisory Committee will face its first big test since the regulator went against its vote on Biogen’s Aduhelm (aducanumab), approving the still-controversial Alzheimer’s drug in June 2021. On Wednesday, the Committee will vote on Amylyx …
Read the full article HERE